share_log

Cognition Therapeutics Shares Are Trading Higher After the Company Provided an Update on a Biomarker Analysis From the Phase 2 SHINE Study in Mild-to-moderate Alzheimer's Disease.

Benzinga ·  Nov 25, 2024 20:45
Cognition Therapeutics Shares Are Trading Higher After the Company Provided an Update on a Biomarker Analysis From the Phase 2 SHINE Study in Mild-to-moderate Alzheimer's Disease.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment